Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Artelo Biosciences Inc (ARTL)

Artelo Biosciences Inc (ARTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition GlobeNewswire - Wed Jul 22, 7:39AM CDT

Review Article Now Published in the British Journal of Clinical Pharmacology Finds Widely Sold Non-Prescription CBD Products at Doses Administered Failed to Provide Adequate Exposure for Positive Biological...

ARTL : 0.8801 (-12.86%)
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions GlobeNewswire - Thu Jul 16, 7:48AM CDT

SOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating...

ARTL : 0.8801 (-12.86%)
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 GlobeNewswire - Tue Jul 14, 7:47AM CDT

SOLANA BEACH, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop...

ARTL : 0.8801 (-12.86%)
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy GlobeNewswire - Mon Jul 13, 8:02AM CDT

Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer Findings suggest broader utility in cancer supportive care, building...

ARTL : 0.8801 (-12.86%)
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury GlobeNewswire - Wed Jul 1, 7:42AM CDT

SOLANA BEACH, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating...

ARTL : 0.8801 (-12.86%)
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 GlobeNewswire - Tue Jun 30, 7:57AM CDT

SOLANA BEACH, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL),  a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop...

ARTL : 0.8801 (-12.86%)
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 GlobeNewswire - Mon Jun 29, 7:45AM CDT

First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research Advancing Development of Novel Biomarkers SOLANA BEACH, Calif., June 29,...

ARTL : 0.8801 (-12.86%)
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success GlobeNewswire - Wed Jun 10, 6:38AM CDT

SOLANA BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...

ARTL : 0.8801 (-12.86%)
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results GlobeNewswire - Thu May 14, 3:05PM CDT

SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...

ARTL : 0.8801 (-12.86%)
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development GlobeNewswire - Tue Apr 28, 7:25AM CDT

SOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments...

ARTL : 0.8801 (-12.86%)

Barchart Exclusives

This High-Yield Bank Stock Just Raised Its Dividend by 11.7%. Barchart - Tue Jul 28, 6:30PM CDT
Citigroup announced an 11.7% increase in its quarterly dividend to $0.67 per share from $0.60 following its strongest quarterly revenue in about a decade. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.